Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Fitusiran by Sanofi for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
Fitusiran is under clinical development by Sanofi and currently in Pre-Registration for Hemophilia A (Factor VIII Deficiency). According to GlobalData,...
Fitusiran by Sanofi for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Fitusiran is under clinical development by Sanofi and currently in Pre-Registration for Hemophilia B (Factor IX Deficiency). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Sanofi's Fitusiran?
Fitusiran is an antisense rnai oligonucleotide commercialized by Sanofi, with a leading Pre-Registration program in Hemophilia B (Factor IX Deficiency)....